Trump’s Pick For FDA Attempts To Distance Himself From Big Pharma

‘Critics are calling attention to the relationship between pharmaceutical companies and President Trump’s nominee to the Food and Drug Administration.
Dr. Scott Gottlieb is promising to recuse himself from more than 20 companies he is involved with should he be accepted as the head of the Food and Drug Administration. Gottlieb made the promise after his relationship with pharmaceutical corporations became a concern to those who oppose his nomination to the FDA. In a letter to the ethics head of the Department of Health and Human Services, Gottlieb promised to recuse himself from more than 20 companies in which he is financially involved.
Gottlieb is a physician who was the deputy commissioner at the FDA from 2005 to 2007 under the Bush administration. He currently sits on the board of several small “biopharma” companies and advises GlaxoSmithKline, the sixth largest pharmaceutical company in the world. Gottlieb also works for venture capital fund New Enterprise Associates and is managing director of investment banking firm TR Winston & Co.’
Read more: Trump’s Pick For FDA Attempts To Distance Himself From Big Pharma